Predictive Value of Aurora-A/STK15 Expression for Late Stage Epithelial Ovarian Cancer Patients Treated by Adjuvant Chemotherapy

Silke Laßmann, Yijun Shen, Uta Jütting, Philipp Wiehle, Axel Walch, G. Gitsch, Annette Hasenburg, Martin WernerClinical 2007 · DOI

Abstract

AURKA overexpression is seen in the majority of late stage epithelial ovarian cancers, most likely due to increased AURKA DNA copy numbers and/or chromosome 20 aneusomy. Importantly, AURKA overexpression may differentially affect taxane and non-taxane-based adjuvant therapy responses. The study sheds new light on AURKA expression and regulation in epithelial cancers in vivo and specifically shows its value as a clinically relevant marker and as a potential therapeutic target per se.
BibTeX
@inproceedings{lamann2007predictive,
  author = {Silke Laßmann and Yijun Shen and Uta Jütting and Philipp Wiehle and Axel Walch and G. Gitsch and Annette Hasenburg and Martin Werner},
  title = {{Predictive Value of Aurora-A/STK15 Expression for Late Stage Epithelial Ovarian Cancer Patients Treated by Adjuvant Chemotherapy}},
  booktitle = {Clinical},
  year = {2007},
  doi = {10.1158/1078-0432.ccr-06-2775},
}

Loading related content...

Figure